Sarepta Gene Therapy Setbacks

Order byBest matchMost fresh

Sarepta, Gene Therapy

Sarepta's Setback Deepens With Another Gene Therapy Fatality

In response to these safety concerns, the U.S Food and Drug Administration (FDA) has requested that the label include a black box warning for acute liver injury (ALI) and acute liver failure (ALF), a...

STAT · 1d

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

· 1d

Exclusive: Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

· 1d

Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

The U.S. Food and Drug Administration is planning to request Sarepta Therapeutics (SRPT.O) to voluntarily stop all shipments of its gene therapy, Elevidys, a source familiar with the matter told Reut...

· 2d

FDA to ask Sarepta to stop shipping Duchenne gene therapy

· 1d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

3don MSN

Sarepta to cut 500 jobs after gene therapy setback, shares jump

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys. Its shares shot up about 40% in extended trading,

Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm downgrading SRPT stock from Hold to Sell.